Robert S. Schwartz, Ph.D.

Representative Matters

• Represented Columbia University against Illumina in a patent litigation related to DNA sequencing products
• Represented Gilead against Teva in an abbreviated new drug application (ANDA) patent litigation related to Atripla® and Truvada® products
• Represented GlaxoSmithKline against Teva in an ANDA patent litigation related to GlaxoSmithKline’s Avodart® product
• Represented Bristol-Myers Squibb against Repligen and Zymogenetics in patent litigations related to Bristol-Myers Squibb’s Orencia® product
• Represented GlaxoSmithKline against Dr. Reddy’s Laboratories, Cobalt Pharmaceuticals, and Spectrum Pharmaceuticals in ANDA patent litigations related to GlaxoSmithKline’s Imitrex® product
• Represented G.D. Searle and Pharmacia against the University of Rochester in a patent litigation related to G.D. Searle and Pharmacia’s Celebrex® product
• Represented Regeneron against Genentech in a patent litigation related to Eylea®

Representative Clients

• Advaxis
• Alnylam
• AstraZeneca
• Bristol-Myers Squibb
• Columbia University
• GlaxoSmithKline
• Regeneron
• Sanofi

Education

• J.D. magna cum laude Pace University School of Law 2003
• • Editor, Pace Law Review
• Ph.D. Biochemistry summa cum laude University of California at Berkeley
• B.S. Biology magna cum laude State University of New York at Albany

Bar Admissions

• New York

Court Admissions

• U.S. Court of Appeals for the Federal Circuit
• U.S. District Court for the Western District of New York
• U.S. District Court for the Southern District of New York

Professional Memberships and Activities

• Authored more than 40 scientific articles and book chapters published in peer-reviewed journals, and numerous articles related to patentability, biologics, and biosimilars
• Frequent speaker at conferences on biologics and biosimilars

• Recognized in Legal 500, Patent Litigation – Full Coverage, 2007, 2014